Active-ingredient Dossier
Semaglutide
Active-ingredient Dossier for Semaglutide (glucagon-like peptide-1 receptor agonist). Australian brands, products, PBS listings, PBAC outcomes — compiled…
- Brand: OZEMPIC
- Brand: WEGOVY
- Brand: RYBELSUS
- Brand: PLOSBRIO
- Brand: POVIZTRA
- Therapeutic area: Endocrinology
What is
Semaglutide Semaglutide is a glucagon-like peptide-1 receptor agonist.
Australian brands containing
Semaglutide — OZEMPIC — WEGOVY — RYBELSUS — PLOSBRIO — POVIZTRA
Therapeutic areas
Semaglutide is registered in endocrinology (3 brands), cardiology (1 brand), and infectious disease (1 brand).
Sponsor landscape
Novo Nordisk Pharmaceuticals markets semaglutide in Australia.
PBS and regulatory activity
One brand containing semaglutide is PBS-listed, with the latest PBS schedule date of 1 May 2026. In the 2024–25 fiscal year, government spending on semaglutide reached AUD 335.78 million across 2.82 million prescriptions. The latest PBAC outcome was recorded on 1 November 2024, and the latest AusPAR was issued on 25 March 2022.